Global Guillain-Barre Syndrome Treatment Market - 2022-2029

Market Overview

The global guillain-barre syndrome treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Guillain-Barre syndrome (GBS), also known as Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), is an acute disorder marked by paralysis of limbs, difficulty breathing moving the face, and inflammatory symptoms throughout the body caused by an immune system attack on the peripheral nervous system.

Market Dynamics

The factors influencing the global guillain-barre syndrome treatment market are the growing demand for the treatment of guillain-barre syndrome and the increasing geriatric population.

The growing demand for the treatment of guillain-barre syndrome is expected to drive the market growth in the forecast period

Guillain-Barre syndrome (GBS) is a disorder characterized by symmetrical limb weakness with hyporeflexia or areflexia and sensory disturbances and cranial nerve deficits in some patients. Guillain-Barre syndrome (GBS) is a rare, rapidly progressive disease caused by nerve inflammation (polyneuritis), which causes muscle weakness and, in some cases, complete paralysis. GBS affects about one or two people per 100,000 people each year. Its exact cause has yet to be discovered. A few days before the onset of the disease, about half of the people who get it have a gastrointestinal or respiratory infection. Strong evidence suggests that the infection triggers an immune response that damages nerve fibers, resulting in weakness and loss of sensation. The sheaths of the nerve fibers are only damaged in milder cases (like the coating around an electric wire). Furthermore, there has been an increase in infections caused by the Epstein-Barr virus, Zika virus, and other viruses because of the increased demand for treatment. According to a report published in 2019 by the Foundation for Peripheral Neuropathy, GBS affects approximately 3,000-6,000 people in the United States each year, fueling the demand for effective treatment, which is expected to drive the market during the forecast period. Improved respiratory care and novel treatment strategies like plasmaphoresis and immunoglobulin have been shown to improve outcomes.

The side effects associated with the treatment of guillain-barre syndrome are expected to hamper the market growth

IVIg is currently the only infusion medication that has been proven to treat GBS. Plasma exchange is another common GBS treatment option, in which blood plasma is removed from the body and separated from the rest of the blood cells. Though rare, IVIg infusion side effects are generally limited to headaches or flu-like symptoms such as nausea, fever, chills, and body aches. The infusion itself may cause mild side effects in some patients. Such as soreness and bruising around the injection site, a sensation of cooling running down the arm and mouth has a metallic taste. According to the 2019 American Society of Aphaeresis (ASFA) guidelines, the primary use of TPE in GBS is an ASFA category I indication. The most common adverse effects associated with TPE cited in the medical literature are allergic reactions to plasma (chills, fever, rash, hives, dyspnea, and stridor), chest pain, dizziness, headache, abdominal pain, anxiety, hypotension, nausea, and vomiting; the incidence is approximately 11% compared to those receiving a 5% albumin solution as a fluid replacement; another adverse effect is symptoms of hypocalcaemia when citrate is used as an anticoagulant.

COVID-19 Impact Analysis

Since the pandemic's start, a lot has been learned about the SARS-CoV-2 virus. Several neurological complications have been reported, studied, and linked to two distinct pathways. In COVID-19 patients, the first proposed mechanism of dissemination, hematogenous (infection of leukocytes or endothelial cells) or trans-neuronal (olfactory or other cranial nerves), causes hyposmia and hypogeusia. A cytokine storm can trigger an abnormal immune-mediated response, leading to severe neurological complications like GBS, encephalomyelitis, and encephalitis. A study conducted in Northern Italy found a significantly higher number of GBS patients and a high frequency of GBS patients with COVID-19 during the COVID-19 outbreak, indicating that SARS-CoV-2 may play a role in triggering GBS. Hence, with the increasing number of covid-19 cases, the demand for the global guillain-barre syndrome treatment market is expected to grow.

Segment Analysis

The intravenous immunoglobulins segment is expected to dominate the market growth

Intravenous immunoglobulin is the most common treatment for Guillain-Barre syndrome (IVIG). The immune system (the body's natural defences) produces harmful antibodies that attack the nerves in Guillain-Barre syndrome. IVIG is a treatment made from healthy antibodies in donated blood. This help prevents nerves from being damaged by harmful antibodies. IVIG is a type of immunoglobulin that is injected directly into a vein. The primary infusion treatment for GBS patients is intravenous immunoglobulin (IVIg). IVIg uses an IV to deliver donor plasma to the body's bloodstream. Immunoglobulins that are healthy contain antibodies that fight and dilute the GBS antibodies that harm the body's nerves. In general, IVIg treatments should be started within two to four weeks of the onset of symptoms. Furthermore, the market is expected to drive by an increase in early regulatory approvals for intravenous immunoglobulin (IVIG) products and rising government support to increase plasma yield during the forecast period.

Geographical Analysis

North America region is expected to hold the largest market share in the global guillain-barre syndrome treatment market

The increasing prevalence of guillain-barre syndrome and the high demand for effective therapy in the region are expected to boost the market growth.

For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in December 2019, the prevalence of GBS is increasing in people over 50 years old, necessitating a large demand due to the US's large geriatric population. Approximately 3,000 to 6,000 people in the United States contract GBS each year, regardless of whether they were vaccinated: 1 to 2 people out of every 100,000 people. Furthermore, the presence of major pharmaceutical companies investing in research to develop novel products and regulatory bodies such as the USFDA that raise awareness about disease and treatment are likely to contribute to market growth.

Competitive Landscape

The guillain-barre syndrome treatment market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are CSL Limited, Grifols S A, Octapharma AG, Kedrion Biopharma Inc, Biotest AG

CSL Limited

Overview: CSL Limited is a multinational specialty biotechnology company based in Australia that conducts research, develops, manufactures, and distributes products to treat and prevent serious human medical conditions. The company was founded in 1916.

Product Portfolio: Privigen is used to treat PI, chronic inflammatory demyelinating polyneuropathy (CIDP) in adults, and chronic immune thrombocytopenic purpura (ITP) in 15 and up. Clinical trials have shown that Privigen IVIg is both safe and effective. Privigen offers a selection of IgG antibodies.

Why Purchase the Report?

Visualize the composition of the global guillain-barre syndrome treatment market segmentation by therapeutics, by route of administration, and distribution channel highlighting the key commercial assets and players.

Identify commercial opportunities in global guillain-barre syndrome treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global guillain-barre syndrome treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global guillain-barre syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers